论文部分内容阅读
目的观察紫杉醇联合顺铂(TP方案)及吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法将84例晚期NSCLC患者随机分成TP组和GP组,入组的患者均接受至少2周期TP和GP的治疗方案,比较两组治疗方案的临床疗效和毒副作用。结果 TP组和GP组的化疗有效率分别为42.9%(18/42)和38.1%(16/36),临床获益率分别为83.3%(35/42)和78.6%(33/42),中位生存期分别294 d和288 d,1年生存率、3年生存率分别为37.3%、9.6%和40.5%、10%,两组比较差异均无统计学意义(P>0.05);主要的毒副作用为骨髓抑制及恶心、呕吐,均可耐受。结论两组治疗方案对晚期NSCLC均有较好的疗效,TP和GP方案可作为晚期NSCLC的一线化疗方案。
Objective To observe the clinical efficacy and side effects of paclitaxel plus cisplatin (TP) and gemcitabine plus cisplatin (GP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty-four patients with advanced NSCLC were randomly divided into TP group and GP group. The patients in the two groups were treated with at least two cycles of TP and GP. The clinical efficacy and side effects of the two groups were compared. Results The effective rates of chemotherapy in TP group and GP group were 42.9% (18/42) and 38.1% (16/36), respectively. The clinical benefit rates were 83.3% (35/42) and 78.6% (33/42) respectively. The median survival time was 294 days and 288 days respectively. The 1-year survival rate and 3-year survival rate were 37.3%, 9.6% and 40.5%, 10% respectively, with no significant difference between the two groups (P> 0.05). The main The side effects of bone marrow suppression and nausea, vomiting, can be tolerated. Conclusion Both treatment regimens have good curative effect on advanced NSCLC. The TP and GP regimens can be used as first-line chemotherapy for advanced NSCLC.